PFE - Sangamo: An Emerging Neurogenetic Therapies Leader

• Sangamo has transitioned to what they called Wave 2 a couple years ago.
• Biogen and Novartis have partnered with Sangamo to pursue gene regulation. These partnerships are actively being grown with two executives leaving Novartis to join Sangamo.
• Research publications indicate IND enabling activities are progressing. Biogen added a new target and Sangamo advanced some programs which should be disclosed in the coming months.
• There are numerous known and probable catalysts in the next six to twelve months.

For further details see: